Mason Carrico
Stock Analyst at Stephens
(0.68)
# 4,089
Out of 4,592 analysts
53
Total ratings
38.5%
Success rate
-4.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mason Carrico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATEC Alphatec Holdings | Initiated Coverage: Buy | $15 | $9.52 | +57.56% | 1 | Jul 23, 2026 | |
| IRTC iRhythm Holdings | Initiated Coverage: Buy | $160 | $117.17 | +36.55% | 1 | Jul 22, 2026 | |
| CTKB Cytek Biosciences | Rated: Buy | $4 → $4.75 | $4.22 | +12.56% | 3 | May 13, 2026 | |
| ESTA Establishment Labs Holdings | Rated: Buy | $90 | $92.54 | -2.74% | 1 | Feb 25, 2026 | |
| GKOS Glaukos | Maintained: Buy | $115 → $145 | $166.72 | -13.03% | 2 | Jan 2, 2026 | |
| PACB Pacific Biosciences of California | Maintained: Buy | $2.5 → $2 | $1.40 | +42.86% | 3 | Nov 10, 2025 | |
| NEO NeoGenomics | Maintained: Buy | $18 → $11 | $15.29 | -28.06% | 4 | Sep 2, 2025 | |
| ILMN Illumina | Rated: Buy | $156 → $110 | $205.10 | -46.37% | 8 | Aug 4, 2025 | |
| PRCT PROCEPT BioRobotics | Initiated Coverage: Buy | $70 | $18.62 | n/a | 1 | Jul 9, 2025 | |
| MYGN Myriad Genetics | Reiterated: Hold | $24 → $30 | $2.86 | n/a | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 → $18 | $43.71 | n/a | 7 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $65 | $47.27 | n/a | 3 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $41 | $28.00 | n/a | 3 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $90 → $63 | $161.99 | n/a | 3 | Feb 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $267.76 | n/a | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 → $32 | $46.32 | n/a | 4 | Dec 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $3.1 → $1.25 | $4.65 | n/a | 2 | May 24, 2022 |
Alphatec Holdings
Jul 23, 2026
Initiated Coverage: Buy
Price Target: $15
Current: $9.52
Upside: +57.56%
iRhythm Holdings
Jul 22, 2026
Initiated Coverage: Buy
Price Target: $160
Current: $117.17
Upside: +36.55%
Cytek Biosciences
May 13, 2026
Rated: Buy
Price Target: $4 → $4.75
Current: $4.22
Upside: +12.56%
Establishment Labs Holdings
Feb 25, 2026
Rated: Buy
Price Target: $90
Current: $92.54
Upside: -2.74%
Glaukos
Jan 2, 2026
Maintained: Buy
Price Target: $115 → $145
Current: $166.72
Upside: -13.03%
Pacific Biosciences of California
Nov 10, 2025
Maintained: Buy
Price Target: $2.5 → $2
Current: $1.40
Upside: +42.86%
NeoGenomics
Sep 2, 2025
Maintained: Buy
Price Target: $18 → $11
Current: $15.29
Upside: -28.06%
Illumina
Aug 4, 2025
Rated: Buy
Price Target: $156 → $110
Current: $205.10
Upside: -46.37%
PROCEPT BioRobotics
Jul 9, 2025
Initiated Coverage: Buy
Price Target: $70
Current: $18.62
Upside: n/a
Myriad Genetics
Oct 11, 2024
Reiterated: Hold
Price Target: $24 → $30
Current: $2.86
Upside: n/a
May 13, 2024
Maintained: Buy
Price Target: $15 → $18
Current: $43.71
Upside: n/a
May 18, 2023
Reiterated: Buy
Price Target: $65
Current: $47.27
Upside: n/a
May 8, 2023
Reiterated: Buy
Price Target: $41
Current: $28.00
Upside: n/a
Feb 16, 2023
Reiterated: Buy
Price Target: $90 → $63
Current: $161.99
Upside: n/a
Dec 16, 2022
Maintained: Buy
Price Target: n/a
Current: $267.76
Upside: n/a
Dec 5, 2022
Reiterated: Buy
Price Target: $30 → $32
Current: $46.32
Upside: n/a
May 24, 2022
Downgraded: Hold
Price Target: $3.1 → $1.25
Current: $4.65
Upside: n/a